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Background: Feline injection site sarcomas (FISS) are aggressive neoplasms that have been associated with
vaccination. In North America the incidence estimates have varied from 1 case of FISS per 1,000-10,000 cats
vaccinated. The aim of this study was to estimate the incidence of FISS in the United Kingdom (UK) in
2007. The ratio of FISS to vaccines sold in the UK was also estimated.
Fourteen FISS were diagnosed by a convenience sample of 34 small animal veterinary practices in the
United Kingdom in 2007 and were used as the numerator for the incidence estimates. Denominator data
was obtained from the computer systems of each practice. Considering that a single cause relationship
with vaccination is not proven, three different denominators (number of cats registered, the number of cat
consultations undertaken and the number of vaccination visits for cats at the practices) were used to
express the potential variation in risk.
Results: The incidence risk of FISS per year was estimated to be 1/16,000 -50,000 cats registered by
practices, 1/10,000-20,000 cat consultations and 1/5,000-12,500 vaccination visits.
Conclusion: When interpreting these findings, it needs to be taken into consideration that this sample of
practices and their cats may not be representative of veterinary practices and cats at risk of FISS in the UK.
However it can still be concluded with reasonable certainty that the incidence of FISS in the UK is very
low.
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It has been suggested that feline injection site sarco-
mas (FISS) are a potential serious adverse event to
vaccination in cats [1]. The cause of FISS remains
unknown, though various hypotheses regarding caus-
ation have been suggested e.g. vaccination, injection,
trauma [2-5]. Therefore the population at risk of
developing FISS (denominator) remains ill-defined
though may be all cats, only cats visiting veterinary
practices, only cats receiving injections/vaccinations
or another population of cats. This makes incidence
estimates for this disease difficult.
To date all studies that have estimated incidence or
prevalence of FISS have been in North America. The
most recent study, undertaken in 1998–1999 estimated* Correspondence: Rachel. Dean@nottingham.ac.uk
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reproduction in any medium, provided the orthe incidence of FISS to be 0.63 sarcomas/10,000 cats
vaccinated or 0.32 sarcomas/10,000 doses of all
vaccines administered [6]. This estimate included a nu-
merator of 2 cats with FISS and denominator data
from 40 practices. Only cats that had been vaccinated
were included in the population at risk. In 1996, Lester
et al. reported an incidence rate of 1.3 FISS per 1,000
vaccinated cats from a single practice [7]. This study
included 18 cases of FISS in the numerator but the
details of the denominator are unclear. In 1993 Kass
et al. reported a rate of 1.2 cases of FISS per 10,000 fe-
line leukaemia virus (FeLV) vaccinations or 1.5 cases of
FISS per 10,000 rabies vaccinations. These estimates
were based on 29 practices vaccination records and
tumour submissions to a histopathology service [2].
Coyne et al. estimated a prevalence of 2.1 cases/10,000
cat visits or 3.6 cases/10,000 cats. There were 158
tumours in the numerator and 235 practitioners
provided denominator data [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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events to veterinary products, including vaccination, is
coordinated by the Veterinary Medicines Directorate
(VMD). The VMD encourages veterinarians, owners and
members of the public to report potential adverse events
via the Suspected Adverse Reaction Surveillance Scheme
(SARSS). In 2007, 857 reports were received by the
VMD pertaining to cats, 59 of which were related to
suspected injection site sarcomas [9]. To date there are
no published estimates of the incidence of FISS in the
United Kingdom (UK). The aim of this study was to esti-
mate the incidence of FISS across a sample of practices
in 2007. A second aim was to estimate the frequency of
FISS in relation to vaccines sold in the UK in 2007.
Methods
This study was part of a larger epidemiology project
about FISS in the United Kingdom that included the
development of a histopathology definition for FISS
and a case–control study to identify risk factors for
FISS (manuscripts in preparation).
Numerator data
To be included in this study each tumour had to meet
the inclusion criteria for the larger epidemiological study
and be diagnosed in 2007. Each tumour was examined
independently by two specialist veterinary pathologists
and, to be included, had to have a minimum of 7 (out of a
possible 10) features identified as part of the histopathology
study. The 10 features included the presence of: aggregates
of lymphocytes, infiltrative margins, intralesional necrosis,
perilesional scarring,/inflammation, adjuvant-like material
in macrophages, medium-high mitotic rate, giant cells and
types of cellular differentiation (manuscript in preparation,
Dean et al.). To be included in the estimate of incidence
the FISS had to be diagnosed at the practices for which
denominator information was available.
Denominator data
Small animal and mixed practices in the United Kingdom
that routinely submitted samples to 4 diagnostic histopath-
ology laboratories (Abbey Veterinary Services, Newton
Abbot: Animal Health Trust, Newmarket, University of
Glasgow, IDEXX laboratories Ltd, Wetherby) were invited
to participate in an epidemiological study concerning FISS.
A letter was sent to all 2330 practices twice, 3 months apart
asking them to participate in the study. All practices that
responded to this letter and joined the study were called
type A practices. If practices that routinely used these
histopathology laboratories later submitted a sample from
a cat that was diagnosed a possible case of FISS they were
again invited to join the study at the time of diagnosis.
Practices that joined as a result of diagnosing a FISS were
called type B practices.For this study of the incidence of FISS only practices
that used management software systems produced by
two specific companies, that had agreed to provide
data for this study, were selected. Written permission
was requested from each practice to allow the software
companies to provide the denominator data. The de-
nominator information for the practices was extracted
by the employees on one software system for their
member practices and by the author for the other.
For the practices that participated, denominator data was
extracted from 1st January to 31st December 2007. Three
different sets of denominator data were extracted:
Denominator 1. The total number of cats registered at the
selected practices at the end of 2007.
Denominator 2. The total number of consultations/
examinations, for which a code was in
the system (e.g. primary consultation,
repeat consultation etc.) recorded for
cats by the selected practices during
2007.
Denominator 3. The total number of vaccinations visits
for which there was a code in the
system for vaccination visit (e.g. booster
vaccination, primary vaccination
courses etc.), recorded for cats by the
selected practices during 2007.
For each of the 3 denominators, 2 different estimates
of incidence were calculated. One set of estimates of
incidence was generated using data from the type A
practices and the cases they reported. A second esti-
mate was made using data from both type A and type
B practices and the cases they reported.
Estimation of incidence
The incidence estimates were generated using the
general formula of:
Incidence of FISS in the UK
¼ Number of new cases of FISS in 2007
Number of cats at risk
in 2007
Ratio between FISS and number of vaccines sold
The total number of feline vaccines sold to practices in
the UK in 2007 was provided by the pharmaceutical
industry. The Royal College of Veterinary Surgeons
register of practices was then used to identify how many
registered practices did small animal work and therefore
were likely to use feline vaccines. All 100% farm animal/
equine practices and referral practices were removed
from the list as they were unlikely to administer cat
vaccines or diagnoses FISS. The number of FISS cases
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was used to calculate the number of FISS/practice in this
study in 2007. This was then multiplied by the total
number of practices that conduct small animal work in
the UK to estimate how many FISS cases may have been
diagnosed in the United Kingdom in 2007.
Results
Participating practices
Of the 2330 practices that routinely submitted pathology
samples to the 4 collaborating laboratories, 260 agreed
to take part in the epidemiology study (response rate
11.2%.) These 260 practices diagnosed 54 FISS in 2007
that met the inclusion criteria for the study. A further
154 practices joined the study after identifying a FISS.
These practices diagnosed 123 cases in 2007 that met the
inclusion criteria for the study. A total of 177 cases of
FISS were therefore identified by the enrolled practices
in 2007.Of the enrolled 414 practice, 309 provided infor-
mation about whether they were computerised for
patient records and 94.5% were (n = 292). Sixty two
practices used the two companies that had agreed to
provide denominator data. Of these 34 practices gave
permission to use the data for the estimation of inci-
dence. This included 22 type A practices that had identi-
fied 3 FISS in 2007, and 12 type B practices that
identified 11 FISS in 2007 (Figure 1).
Estimates of incidence risk of FISS per year
The incidence estimates were very low for all types of
denominators and numerators, ranging from 1 FISS per
50,000 cats registered to 1 FISS per 5,000 cat vaccination
visits (Table 1).
Ratio between FISS and number of vaccines sold
From the RCVS register of practices it was estimated
that there were 3399 practices that did small animal
work (excluding referral practices) and were therefore
likely to vaccinate cats. The pharmaceutical industry
stated that 3,607,510 doses of feline vaccines were sold
to practices in 2007.
Fifty four cases were identified from 260 type A
practices in 2007, which is a rate of 0.21 FISS/practice
per year. If these practices were representative of the
3399 practices that did small animal work in the UK in
2007, then 706 FISS may have occurred across all small
animal practices in 2007. This would suggest that 0.0002
FISS occur per vaccine sold per year or 1 FISS occurs
for every 5,000 vaccines sold per year.
The 414 type A and type B practices identified 177
FISS, which is a rate of 0.42 cases/practice per year. If
these practices were representative of the 3399 practices
that did small animal work in the UK in 2007, then 1453
FISS may have occurred in 2007. This would suggestthat 0.0004 FISS per vaccine sold per year or 1 FISS
occurs for every 2,500 vaccine sold per year.
Discussion
The estimates of incidence of FISS in this study were
very low for all denominators used and it therefore
seems justified to conclude that the incidence risk of
cats suffering from FISS is very low in United Kingdom.
The incidence estimates reported in this study lie within
the range of incidence estimates for North America pre-
viously reported in the veterinary literature [2,5,7].
It was not possible to calculate the true incidence risk
of FISS in the UK as neither accurate numerators
or denominators were available. Establishing accurate
estimates is very difficult for rare diseases. This is
compounded by the fact that the epidemiological under-
standing of the risk factors associated with FISS develop-
ment remains poor, therefore the population at risk is
unknown. It has been suggested that vaccination could
be a risk factor for FISS, but the evidence for a causal re-
lationship is weak, and therefore vaccinated cats are
likely to be an inappropriate denominator [2,3]. It has
also been suggested that other injectable products may
play a role in FISS development, [4,5], hence multiple
denominators were used. Whatever the causal factors
for FISS, the risk of developing this tumour to an indi-
vidual cat is very low.
In the current study numerator and denominator data
were only available for a small number of practices. Inci-
dence and prevalence estimates for FISS in previous
studies have also been based on a small number of
practices [2,6,7]. The reasons why some practices chose
to be in this study, used particular computer software
systems and allowed access the data, were no doubt
numerous. This small sample of practices is unlikely to,
but may, represent the general population of veterinary
practices in the UK. It was not possible to include all
practices in the UK in this study but more practices
would have potentially generated more reliable estimates
of FISS. It is unknown what an ‘average’ practice is like
so the external validity of this study is highly question-
able. The incidence estimates for type A practices alone
were much lower than the incidence estimates when
data from type A and type B practices were used. This is
to be expected as type B practices joined the study because
they had identified a possible FISS. It is unclear whether
type A practices or type A and type B practices are more
representative of small animal practices in the UK.
The estimates of incidence given in this study were
based on a number of assumptions, as limited data were
available. The numerator used in the final estimates was
low due to the limited number of practices with denom-
inator data available and the low frequency of FISS in
the feline population. It is possible that more FISS did
22 Type A practices 3 cases of FISS identified by Type A 
practices
11 cases of FISS identified by Type B 
practices
12 Type B practices
62 practices used the practice 
management software people
34 practices gave permission to use 
data
14 cases of FISS identified by 34 
selected practices
414 practices enrolled in study
309 practices provided information 
about the computer software 
systems
260 practices agreed to participate from initial letter: 
–Type A practices
154 practices agreed to participate after diagnosing a 
possible case of FISS: – type B practices
Identified 177 cases of FISS
Identified 54 cases of FISS
Identified 123 cases of FISS
2330 practices use histopathology 
labs and invited to join the study
Figure 1 Flow diagram demonstrating how practices and Feline injection site sarcoma (FISS) tumours were selected for inclusion in
the incidence estimates. Practice type A responded by initial letter of invitation at the start of the study; Practice type B responded to the
pathology report addendum after identifying a case during the study period.
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the investigator. Potential reasons not to report a FISS
amongst others could be lack of permission from the
owner to enter the tumour into the study, a lack of time
to complete the paperwork or an owner declined histo-
logical examination of a FISS.
Multiple denominators were used in this study as it was
not known what/who the population at risk was. It is pos-
sible that all cats are at risk of developing FISS, or just
those visiting veterinary practices. Alternatively it may
only be cats that were vaccinated/injected if indeed this is
required for tumorigenesis. The denominators were
chosen either because they were the same as those used in
previous studies so comparisons could be made, wereassociated with some of the hypotheses surrounding FISS
or it was possible to extract this information from both
computer software systems with relative ease [2,6,7]. The
number of cats currently registered should provide a
reasonable estimate of the number of cats who could
potentially be identified as cases if they developed FISS
and probably represent the most reliable denominator.
The number of cat consultations recorded by a practice
was used as another denominator as this could be another
possible population at risk. The total number of con-
sultations was used regardless of whether it was an initial
or repeat consultation since it was not possible to separate
the types of consultations for all practices from the infor-
mation provided. It is likely that some, but not all, cats
Table 1 Estimates of incidence of FISS in the United Kingdom in 2007
Number (type)
of practices
Numerator
(FISS)
Denominator Incidence risk of FISS per year
22 (A only) 3 122,736 cats registered 0.00002 FISS per cat registered 1 FISS per 50,000 cats registered
34 (A and B) 14 206,942 cats registered 0.00007 FISS per cat registered 1 FISS per16,666 cats registered
22 (A only) 3 54,732 cat consultations 0.00005 FISS per cat consultations 1 FISS per 20,000 cat consultations
34 (A and B) 14 102,696 cat consultations 0.00001 FISS per cats consultations 1 FISS per 10,000 cat consultations
22 (A only) 3 38,205 cat vaccination visits 0.00008 FISS per cat vaccination visits 1 FISS per12,500 cat vaccination visits
34 (A and B) 14 58,516 cat vaccination visits 0.0002 FISS per cat vaccination visits 1 FISS per 5,000 cat vaccination visits
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jection such as a vaccination or other product. Therefore
the first two denominators may be a more realistic repre-
sentation of the population at risk, therefore these
estimates may be the most accurate. It was not possible to
determine from the practice data how many injections
had been given to cats in 2007. This would provide very
valuable data if it became available. The number of
vaccinations recorded as being administered was used as
the third denominator. However, this does not take ac-
count of the currently accepted theory that other vaccines
may be involved in the aetiology of FISS, and it therefore
may be the most inaccurate denominator to use, of the
three presented here.
The reliability of the denominator data is questionable
for many reasons. The data came from the two different
sources and was extracted from practices in two differ-
ent ways. The way in which cats are added and removed
from a practice database is unknown and probably
differs between practices. The accuracy of the extracted
data was entirely reliant on the accuracy of the entered
data. Practices may code vaccinations, consultations etc.
in many different ways so a code in a software system
in one practice may mean something else entirely by an-
other practice. The denominators used in this study had
many limitations and more sophisticated methods need to
be explored to provide more accurate data about the vet
visiting population of cats and disease prevalence and inci-
dence. This issue is currently be addressed in the UK by
the work of SAVSNET (http://www.liv.ac.uk/savsnet) and
VetCompass (http://www.rvc.ac.uk/vetcompass) who are
involved in developing methods for disease surveillance in
small animal veterinary practices in the United Kingdom.
This study indicates that more injection site sarcomas
occur in the United Kingdom than were reported to the
Veterinary Medicines Directorate (VMD) in 2007 [9].
This study only included the practices enrolled in the
study and 4 diagnostic histopathology laboratories. It is
not possible to make estimates of how many more FISS
may have been diagnosed at other laboratories in 2007
but there is no doubt that there would have been more
FISS diagnosed during this period. If the caseload of
these practices does represent all practices in the UnitedKingdom in, the number of cases of FISS could be over
1400 though the true number of FISS remains unknown.
It is unknown whether or not the tumours in this study
have also been reported to the VMD. Or if the cases
reported to the VMD would fulfil the criteria used in
this study. There are probably numerous reasons why
the number of FISS reported to the VMD was lower
than the number identified in this study. The VMD’s
suspected adverse reaction surveillance scheme (SARSS)
is passive whereas this study was a more active form of
surveillance. The number of cats in the UK is thought to
be around 10.3 million, so this disease is still very rare in
the cat population in the UK [10].
Vaccination protocols vary between countries, so if
vaccination is involved in the aetiology of FISS, then the
incidence of this disease would be expected to be differ-
ent. For example, rabies vaccination is not a routine pro-
cedure for cats in the UK but is in other parts of the
world. It is interesting that the incidence estimates in this
study are similar to, but not the same, as some of those
from North America [2,6,8], yet vaccination protocols
differ between the countries. This highlights the fact that
it is not possible to extrapolate these estimates of inci-
dence to other countries but it appears that these
tumours are rare in all of the cat populations studied.
The ratio of FISS to the number of vaccines sold in
the UK was estimated, as the number of vaccines sold
has been used before in studies in North America. The
number sold does not necessarily equate to number
administered (as some batches maybe faulty or exceed
their shelf-life) and if the enrolled practices are not rep-
resentative of the veterinary practices in the UK then the
estimate of the number of FISS in 2007 will be inaccur-
ate. It is interesting to note that the estimated ratio of
FISS per vaccines sold (1 FISS/2,500 - 5,000 vaccines
sold), and the incidence estimate that used vaccinations
visits recorded (1 FISS/5,000-12,500 vaccines recorded
as administered) are different. One possible explanation
is that when a cat receives two consecutive vaccinations
(e.g. kitten and re-vaccination protocols) it is only
recorded in the system once. These estimates of inci-
dence are made in two completely different ways and
using different numbers of cases and practices. It is
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most accurate is.
Conclusion
Many assumptions were made when calculating these
estimates of incidence so they must be interpreted and
reported with caution. However it can be concluded that
whilst these tumours are more common than currently
reported to the VMD, the incidence is still very low in
the UK cat population. If more accurate estimates of the
incidence of FISS are required further work is needed.
However FISS is a rare disease and there are many more
feline diseases that have much more significant morbid-
ity and mortality and therefore a greater effect on cat
welfare than this tumour.
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